Primary sponsor: The Walton Centre NHS Foundation Trust, University of Liverpool, UK
Collaborating group: European Organisation for Research and Treatment of Cancer (EORTC); Trans Tasman Radiation Oncology Group (TROG)

Title

Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Summary

This trial aims to determine whether early adjuvant fractionated external beam radiotherapy reduces the risk of tumour recurrence compared to active monitoring in newly diagnosed atypical meningioma.

Atypical meningioma is a tumour that arises from the lining of the brain. It mostly affects adults, with most patients in the 40-60 year age group. The primary treatment for atypical meningioma is surgical removal, but with surgery alone, up to 40% of patients will experience recurrence. Because of this risk, some clinicians give early radiotherapy, whilst others advise regular monitoring with radiotherapy given only at recurrence. Currently, there is no consensus as to which of these two approaches is best. This randomised controlled trial will compare the two approaches, and aims to determine whether early radiotherapy reduces the risk of tumour recurrence compared to regular monitoring in newly diagnosed atypical meningioma.

Participating centres

Accrual target

30

Current accrual

Expected Date of Accrual Completion

September 2020

Trial chairperson

Dr Gail Ryan, Peter MacCallum Cancer Centre, VIC

Trial contact

TROG Trial Coordinating Centre

Phone: +61 2 4014 3911
Email: ROAM@trog.com.au

Trial resources for TROG members

Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Atypical meningioma is a tumour that arises from the lining of the brain. It mostly affects adults, with most patients in the 40-60 year age group. The primary treatment for atypical meningioma is surgical removal, but with surgery alone up to 40% of patients will experience recurrence. Because of this risk, some clinicians give early radiotherapy, whilst others advise regular monitoring with radiotherapy given only at recurrence. Currently there is no consensus as to which of these two approaches is best. This randomised controlled trial will compare the two approaches, and aims to determine whether early radiotherapy reduces the risk of tumour recurrence compared to regular monitoring in newly diagnosed atypical meningioma.

Primary Sponsor

The Walton Centre NHS Foundation Trust, University of Liverpool, UK

Collaborating Groups

European Organisation for Research and Treatment of Cancer (EORTC) ; Trans Tasman Radiation Oncology Group (TROG)

Participating Centres

Final Accrual

15

Current Accrual

Expected Date of Accrual

September 2021

Closing Date of Accrual

21st May 2021

Trial Chairperson

Dr Gail Ryan, Peter MacCallum Cancer Centre, VIC

Trial Contact

ROAM@trog.com.au

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a